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Abstract
Cerebral calcification may be caused by several potentially treatable conditions, however, inmost cases it does not receive special
attention in clinical practice. From the point of view of etiology, the diseases associated with cerebral calcification can be divided
into two main groups: idiopathic (mostly incurable) and secondary (potentially treatable). The first group includes mainly the
hereditary diseases identified before 2021 (primary familial brain calcification subtypes, previously known as Fahr’s disease or
Fahr’s syndrome). In contrast, the second group includes diseases with cerebral calcification that develop generally as a conse-
quence of metabolic/endocrine/autoimmune abnormalities. The aim of our research was to present hereditary and non-hereditary
etiologies associated with extensive brain calcification. We compare the detailed clinical, radiological and laboratory results of 6
patients with prominent cerebral calcification identified in our clinic in the last 3 years (idiopathic and secondary etiologies as
well). Our research draws attention to the complexity of the etiologies in the context of cerebral calcification. We recommend,
beside NGS-based sequence analyses, the application of array comparative genomic hybridization as well, to identify potential
genetic etiologies associated with brain calcification.
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Introduction
Central nervous system calcification may be associated with
several different underlying etiologies (Batla et al. 2017;
Donzuso et al. 2019; Saleem et al. 2013; Westenberger et al.
2019). However, the clarification of the underlying diseases is
often neglected in the daily clinical practice, even though up to
20% of the head CT scans in the elderly population reveal
some degree of brain calcification (Yamada et al. 2013).
There have been several attempts to date to classify the brain
calcifications, based on location, etiology, and symptomatol-
ogy (Oliveira et al. 2013; Savino et al. 2016). Manyam (2005)
proposed the following classification on anatomical basis: (1)
strio-pallido-dentato calcinosis, (2) bilateral strio-pallidal cal-
cinosis and (3) bilateral cerebellar calcification. The use of this
classification is complicated by the fact that there is no strong
correlation between the localization of calcification and the
underlying etiology. From this perspective the main groups
are the followings: (1) physiologic/age-related, (2) vascular,
(3) neoplastic, (4) infectious, (5) metabolic/endocrine, (6)
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inflammatory/autoimmune, (7) genetically determined disor-
ders and (8) toxic diseases (Kıroğlu et al. 2010; Saade et al.
2019; Saleem et al. 2013; Taborda et al. 2017) (Table 1). A
serious shortcoming of the above etiological classification is
that individual diseases can even be classified into several
groups. Depending on the localization and the etiology of
brain calcification, a wide range of potential neurological
(e.g. movement disorder), psychiatric and musculoskeletal
symptoms may appear, however, these symptoms are not re-
ally helpful during the differential diagnostic process (Batla
et al. 2017; Kostić and Petrović 2017). From the etiological
perspective, the greatest challenge in adult neurological pa-
tient care is to differentiate between endocrine/metabolic (po-
tentially treatable) and the genetically determined (mostly in-
curable) forms of brain calcification. Therefore, diagnostic
algorithms have been presented to help in distinguishing
(Bonazza et al. 2011; Saleem et al. 2013).
Extended genetic studies revealed new genes responsible
for primary familial brain calcification (previously known as
idiopathic basal ganglia calcification /IBGC/ or Fahr’s disease
or Fahr’s syndrome) (Table 2) (Batla et al. 2017;
Westenberger et al. 2019). These are mostly autosomal dom-
inantly inherited (e.g. SLC20A2), however, some types show
autosomal recessive inheritance (e.g. MYORG).
The aim of this case series is to compare the clinical, lab-
oratory, and radiological features of hereditary and non-
hereditary etiologies identified in association with extensive
cerebral calcification.
Case reports
Case 1 – Mos 46,XY,der(11)t(X;11)(p21.1;q14.2)[152]
/46,XY[48]
The 57-year-old male patient was admitted to the outpatient
clinic due to severe gait disturbance, swallowing difficulty,
and speech disorder. It should be noted from the previous
medical history of the patient that he suffered from an ische-
mic stroke in the territory of the right middle cerebral artery
2 years prior to admission. The following neurological symp-
toms were observed during the detailed examination: upward
gaze palsy, abnormal saccadic eye movements, severe dysar-
thria and dysphagia, prominent four-limb ataxia, severe trunk
ataxia, tremor (resting and postural), urinary incontinence
(Supplementary video 1). No signs of dysmorphia were ob-
served on the patient. The performed detailed laboratory tests
demonstrated normal results except for slightly elevated se-
rum alkaline phosphatase and urine calcium levels (Table 3).
Routine electroencephalography (EEG) found no epileptiform
abnormalities, however, focal slowing in the right frontal-,
temporal- and left frontal regions was detected as well. The
Addenbrooke’s cognitive examination (ACE) detected a mild
cognitive decline (76/100), principally the anterograde mem-
ory and the attention-related functions were involved.
Extensive intracerebral calcification was revealed by head
CT scan (Fig. 1 – Case 1). It showed primarily the involve-
ment of the basal ganglia, cerebellum, deep white matter, and
Table 1 Etiologies of brain calcification (Based on the following
articles: Kıroğlu et al. 2010; Saade et al. 2019; Saleem et al. 2013,
Taborda et al., 2017) (Abbreviations: ERCC8 – excision repair cross-
complementing, group 8; GNAQ – guanine nucleotide-binding protein,
Q polypeptide; GNAS – GNAS complex locus; HIV – human immuno-
deficiency virus; JAM2 – junctional adhesion molecule 2; MYORG –
myogenesis-regulating glycosidase; NF1 – neurofibromin 1; NF2 –
neurofibromin 2; PDGFB – platelet-derived growth factor, beta polypep-
tide; PDGFRB – platelet-derived growth factor receptor, beta; PTCH2 –
patched 2; SLC20A2 – solute carrier family 20 (phosphate transporter),
member 2; STX16 – syntaxin 16; TORCH – toxoplasmosis, other agents,
rubella, cytomegalovirus, herpes simplex; TREX1–3-prime repair exonu-
clease 1; TSC1 – TSC1 gene; TSC2 – TSC2 gene; XPR1 – xenotropic and
polytropic retrovirus receptor)
Etiology group Main subtypes
(1) Physiologic/age-related Habenular-, pineal-, falcial-, dural-, tentorial-, choroidal- and bilateral basal ganglia calcification
(2) Vascular Vasculitis (chronic), arteriosclerosis (primary), arteriovenous- or cavernomatous malformation, aneurysms
(3) Neoplastic Intraaxial (e.g. astrocytoma, oligodendroglioma, ganglioglioma,
medulloblastoma, metastasis), extraaxial (e.g. meningioma,
craniopharyngioma, pineal tumor, germ cell line tumor)
and intraventricular (ependymoma) neoplasms
(4) Infectious TORCH, congenital Zika infection, HIV encephalitis, neurocysticercosis,
brucellosis, Cryptococcus neoformans infection
(5) Metabolic/endocrine Hypothyroidism, hypoparathyroidism (idiopathic, secondary
(e.g., postthyroidectomy), pseudo-, pseudo-pseudo), hyperparathyroidism
(6) Inflammatory/autoimmune disorders Systemic lupus erythematosus, cerebral sarcoidosis
(7) Genetically determined disorders SLC20A2, PDGFRB, PDGFB, XPR1, MYORG, JAM2, STX16,
GNAS, PTCH2, ERCC8, TREX1, TSC1, TSC2, GNAQ, NF1,
NF2, 6p25 deletion syndrome
(8) Toxic diseases Lead or carbon monoxide poisoning
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brainstem (pons). Abdominal MRI detected cavernomatous
hemangiomas, which may partly explain the mild elevation
of alkaline phosphatase. Chest X-ray confirmed pneumonia,
which was presumably associated with elevated urinary calci-
um level. Extensive genetic studies (clinical exome sequenc-
ing searching for the known genes behind idiopathic basal
ganglia calcification, then G-banded karyotyping, array com-
parative genomic hybridization (aCGH), fluorescence in situ
hybridization and multiplex ligation-dependent probe ampli-
fication) were performed on DNA isolated from blood and
oral mucosa cells, respectively. Clinical exome sequencing
indicated a deletion in chromosome 11, which prompted
aCGH analyses. A mosaic form of presumed unbalanced
translocation between chromosome X and 11 was detected.
The karyotype of the patient was the following: mos
46,XY,der(11)t(X;11)(p21.1;q14.2)[152]/46,XY[48] that re-
sulted in Xpter→21.1 duplication and 11qter→ 14.2 deletion.
The gene content of the affected chromosomal regions was
determined by UCSC Genome Browser, Ensembl BioMart
and OMIM databases and is included in the Supplementary
file 1. Given the newly identified genetic abnormality, it was
not possible to initiate specific treatment in the absence of
scientific data. The patient has 5 asymptomatic children (3
daughters and 2 sons) in whom the chromosomal rearrange-
ment was not found (only blood samples were analyzed; no
calcification was observed in the performed skull CT scans)
(Supplementary file 2). The father of the proband died of a
lung neoplastic process; however, he did not suffer from a
similar disease. Her mother was not facilitated to genetic test-
ing due to her old age (82 years).
Case 2 – SLC20A2
The 68 years old female patient was admitted to our clinic
with prominent articulation difficulty and gait abnormality.
Her symptoms appeared first at the age of 42, and then
progressed gradually until she was only able to walk safely
with a rollator. The major features demonstrated by neurolog-
ical examination of the patient (Supplementary video 2) were
muscle hypotonia and mainly left-sided bradykinesia.
Choreiform dyskinesis was observed in the right upper limb.
Her gait was unstable lacking the synkinesis of upper limbs
Table 2 Genetic subtypes of primary familial brain calcification
(Abbreviations: AD – autosomal dominant; AR – autosomal recessive;
BBB – blood brain barrier; JAM2 – junctional adhesion molecule 2;
MYORG – myogenesis-regulating glycosidase; N.D. – no data; PDGFB
– platelet-derived growth factor, beta polypeptide; PDGFRB – platelet-
derived growth factor receptor, beta; PFBC – primary familial brain cal-
cification; SLC20A2 – solute carrier family 20 (phosphate transporter),
member 2; XPR1 – xenotropic and polytropic retrovirus receptor)
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and turning from 6 steps. No other pathological abnormalities
other than low 25-OH D3/D2-vitamin levels were detected in
the performed detailed laboratory tests (Table 3). The routine
EEG showed normal brain activity without the evidence of
epileptic discharges. The neuropsychological assessment re-
vealed the signs of mild cognitive impairment (ACE: 81/100
points). In the background of this deterioration, working
memory and executive dysfunction were identified.
Regarding attention-related tasks, a slowing was detected as
well. The performed head CT scan showed an extensive sym-
metrical cerebral calcification with the involvement of basal
ganglia, cerebellum and deep white matter (Fig. 1 – Case 2).
The performed NGS-based genetic test (clinical exome se-
quencing and deletion/duplication analysis) revealed a variant
of unknown significance (class 3; PolyPhen: probably dam-
aging; Align-GVGD: C0; SIFT: deleterious; MutationTaster:
disease causing) in heterozygous state in the SLC20A2 gene
(c.1535G >A; p.Gly512Asp). The detected heterozygous mu-
tation affecting a single nucleotide in SLC20A2 gene is very
rare and was not previously described in 360 Hungarian con-
trol samples or in the gnomAD, ClinVar and HGMD data-
bases, which supported the clinical diagnosis. In view of the
patient’s parkinsonism, we tried rasagiline, levodopa +
benserazide and amantadine sulphate treatments, without
marked clinical benefit. The proband has only one son
(asymptomatic), whose head CT scan did not show
intracranial calcification, although he had reached the predi-
lection age (Supplementary file 2). He is not carrier for his
mother’s SLC20A2 mutation.
Case 3 – SLC20A2
A 57-year-old female patient was referred to our clinic with
the followings. The patient noticed that her right hand was
shaking at rest and she was unable to express herself period-
ically for the last two months. The patient was undergoing
psychiatric care due to depression. The following abnormali-
ties were observed in the neurological status of the patient:
psychomotor slowness, cognitive deficit symptoms, square
wave jerks and gaze-evoked nystagmus, dysarthria, cerebellar
symptoms (dysmetria on the right hand, dysdiadochokinesis,
intentional tremor), postural and resting tremor, bradykinesia
predominantly at the right side, antalgic gait, absent
synkinesis in the right side, tactile hypesthesia in the right
body side (Supplementary video 3). The laboratory tests de-
lineated no abnormalities except for low vitamin D and slight-
ly elevated alkaline phosphatase levels (Table 3). The result of
routine EEG was normal. The conducted neuropsychological
assessment revealed signs of psychomotor slowness and low-
er working memory capacity. The previously performed head
CT scan confirmed extensive periventricular, basal ganglia,
and cerebellar calcification (Fig. 1 – Case 3). The genetic
Fig. 1 Head CT images (3 sections: centrum semiovale, basal ganglia,
posterior fossa) of the probands (Abbreviation: 1–6 – the number of the
case; SLC20A2 – solute carrier family 20 (phosphate transporter),
m em b e r 2 ; S T X 1 6 – s y n t a x i n 1 6 ; t ( X ; 1 1 ) – m o s
46,XY,der(11)t(X;11)(p21.1;q14.2)[152]/46,XY[48])
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analysis (bidirectional sequencing of the 4 most commonly
involved genes (SLC20A2, PDGFB, PDGFRB and XPR1))
detected a known pathogenic mutation in heterozygous state
in the SLC20A2 gene (c.82G >A, p.Asp28Asn) (Chen et al.
2013). The detected heterozygous mutation affecting a single
nucleotide in SLC20A2 gene is very rare and was not previ-
ously described in 360 Hungarian control samples or in the
gnomAD databases. It is classified as “likely pathogenic –
idiopathic basal ganglia calcification type 1” according to
the ClinVar and HGMD databases. In the treatment of the
patient, the primary goal was to manage the psychiatric symp-
toms, therefore venlafaxine, clonazepam and quetiapine drugs
were applied. During the segregation analysis of the family,
we also found the mutation in the so far asymptomatic brother
of the proband (receiving anticoagulant therapy for deep vein
thrombosis), which correlated with the positive head CT result
(Supplementary file 2).
Case 4 – STX16
The 47-year-old male patient was admitted to our clinic with
the history of progressive, pronounced gait disorder for
2 years. He also fell several times in the year before his ad-
mission and suffered from a fracture of right wrist in connec-
tion with one such fall. Detailed neurological examination
detected severe cerebellar symptoms (four-limb ataxia,
dysdiadochokinesis, disruption of alternating movements,
dysar thr ia) as wel l as bi la tera l pyramidal s igns
(Supplementary video 4). There were abnormalities in labora-
tory results consistent with secondary hyperparathyroidism
(Table 3). The routine EEG did not detect epileptiform dys-
function; however, it showed a slow wave activity in the right
occipital region. The neuropsychological assessment raised
the possibility of major neurocognitive disorder (ACE: 55/
100 points). A marked decrease was observed in the tasks
examining attention- and memory- and language-related func-
tions. The head CT scan showed pronounced bilateral basal
ganglia, cerebellar and brainstem calcification (Fig. 1 – Case
4). The genetic analysis (clinical exome sequencing confirmed
by Sanger sequencing) detected a large, previously not pub-
lished deletion (NM_001001433.3(STX16):c.393 +
557_792 + 364del) in the STX16 gene (chr20:57243567–
57,246,544 in GRCh37 or chr20:58668511–58,671,488 in
GRCh38). This alteration was also indicated as pathogenic
in ClinVar database (VCV000978043.1) submitted by
Undiagnosed Diseases Network, NIH in 2020. The patient
received cholecalciferol and calcium supplementation. The
proband has an asymptomatic sister whose head CT
scan revealed cerebral calcification identical to her
brother and the same mutation was also found. (The
rest of the family refused to undergo a detailed medical
examination.) (Supplementary file 2).
Case 5 – Infiltration of the parathyroid gland
The 34-year-old female patient was admitted due to progres-
sive speech disorder, gait disturbance, and intermittent blurred
vision in the left eye. Based on heteroanamnestic data, it was
hard to express herself for half a year and counting problems
were reported as well. Concurrently, she presented forgetful-
ness, emotional lability, lack of motivation, and clumsiness in
her hands as well. Regarding the previous medical history,
antecedent previous syphilis infection should be noted (no
documentation was available). In an earlier laboratory study
of the patient, anti-dsDNA antibody level was significantly
elevated (79 U/ml), however, the level of antinuclear antibod-
ies was normal. The patient had two miscarriages. The neuro-
logical phenotype was dominated by cerebellar symptoms,
dysarthria, dysphagia, gait-activated dystonia and emotional
instability (Supplementary video 5). The endocrine laboratory
tests showed alteration compatible with the diagnosis of
normocalcemic hypoparathyroidism (Table 3). The result of
the routine EEG was normal. The neuropsychological assess-
ment revealed significant cognitive involvement (ACE: 61/
100 points) as well as impairment of language functions and
abnormalities in retrograde memory. Head CT scan of the
patient showed extensive calcification in the cerebellum, pons,
basal ganglia, and subcortical regions (Fig. 1 – Case 5). No
abnormality was demonstrated in thyroid ultrasound. A de-
tailed dermatological examination revealed no abnormality
suggestive of systemic lupus erythematosus. The performed
whole exome sequencing did not identify any known or po-
tential genetic abnormality underlying the clinical phenotype.
Given that normocalcemic hypoparathyroidismmay be due to
a decreased reserve capacity of the parathyroid gland (Cusano
et al. 2013), we considered the infiltration of the parathyroid
gland by syphilis as an etiological factor, however, the possi-
bility of neurolupus cannot be ruled out with absolute certain-
ty (Andres et al. 2009). The patient required the initiation of
tiapride and pyridostigmine therapies for progressive chorea
and dysphagia. Tiapride resulted in a significant improvement
of chorea.
Case 6 – Secondary hypoparathyroidism
The 72-year-old female patient was admitted to our depart-
ment due to a temporary motor aphasia. After admission, the
speech disorder was no longer observed, however, four limb
hypotonia as well as cerebellar alterations (disturbance of al-
ternating movements, intentional tremor, ataxic gait) and bi-
lateral upper limb postural tremor were detected
(Supplementary video 6). Regarding her previous medical
history, total thyroidectomy due to follicular adenoma
(oncocytic type; histological specimens also included the
parathyroid glands) should be highlighted. The laboratory test
abnormalities were consistent with hypoparathyroidism
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(Table 3). The routine electroencephalography was negative.
Regarding cognitive alterations, mild impairment of executive
functions and verbal fluency was found. The performed head
CT scan showed extensive deposition of the calcium bilater-
ally in the basal ganglia and cortical regions (Fig. 1 – Case 6).
Secondary (postthyroidectomy) hypoparathyroidismwas con-
sidered in the background of symptoms of the patient. The
patient was treated with cholecalciferol and calcium
supplementation.
Discussion
As the scientific literature expands, identifying an etiology
underlying cerebral calcification is a real diagnostic challenge,
especially in the adult care. Occasionally, a definitive diagno-
sis can be made by analyzing only clinical symptoms or ra-
diological abnormalities. However, in most cases, extensive
clinical and laboratory studies are needed to find the diagno-
sis. Investigations should focus on potentially treatable etiol-
ogies, most often due to endocrine causes. Nevertheless, the
identification of genetically determined diseases is essential
mainly in terms of future clinical trials based on targeting
the identified genetic alterations. The main goal of our re-
search was to compare the clinical, laboratory and radiological
characteristics of six patients identified with extensive cere-
bral calcification. Four hereditary and two non-hereditary eti-
ologies were found associated with brain calcification.
In case 1 (t(X;11)), we identified a novel, previously not
repor ted unbalanced chromosomal t rans locat ion
(46,XY,der(11)t(X;11)(p21.1;q14.2)[152]/46,XY[48]) with
unknown significance. The clinical symptoms correlated with
the head CT pictures, namely, dysphagia could be explained
by brainstem involvement, ataxia by cerebellar involvement.
The laboratory examination of endocrine parameters of our
patient did not contain any relevant pathological abnormalities
similarly to other hereditary etiologies (Bonazza et al. 2011).
Despite, the lack of specific complaints (e.g. headache -
PDGFB) and signs (e.g. parkinsonism - SLC20A2; seizure -
endocrine disorder) (Batla et al. 2017; Nicolas et al. 2013a, b)
we made clinical exome sequencing, which indicated a dele-
tion in chromosome 11, which prompted aCGH analyses.
Regarding the pathogenicity of the genetic abnormality found
in our patient, it was important to exclude other hereditary
causes with high certainty. Therefore, we examined all the
genetic alterations associated with cerebral calcification re-
ported in the scientific literature (single nucleotide variations,
deletions and duplications), but no pathogenic alteration was
found (Batla et al. 2017; Tadic et al. 2015). The performed
aCGH test detected a novel unbalanced translocation between
chromosomes X and 11 in mosaic form and it was confirmed
by FISH and MLPA analyses as well. This difference was not
found in the offsprings (non-germline). The mechanism
leading to this genetic alteration is still unknown. The disease
may be caused by an increase in the dosage of gene products
formed in connection with the partial duplication of the
pseudoautosomal region of the short arm of chromosome X
or a decrease in the dosage of gene products in the partially
deleted region of the long arm of chromosome 11. However,
the pathogenicity of the alteration cannot be clearly stated,
further studies/case reports are needed to clarify this question.
Genes affected by this translocation have not been clearly
associated with cerebral calcification to date. The interpreta-
tion of the genetic abnormality observed in the patient is fur-
ther complicated by the fact that the genetic abnormality was
found only in the blood and not in the sample taken from the
oral cavity. We have no knowledge of whether the genetic
abnormality is present in other tissues (e.g. in the central ner-
vous system). Consequently, it is very difficult to give a
genotype-phenotype correlation, as it can be very different
depending on the tissue-specific distribution. Cases 2 and 3,
although the genetic mutation identified in the background
involved the same gene (SLC20A2), the clinical picture was
only partially matched. Although parkinsonism was observed
in both cases (consistent with the literature data (Batla et al.
2017)), choreiform symptoms predominated in Case 2, where-
as cerebellar symptoms dominated in Case 3. A detailed lab-
oratory examination did not show significant difference be-
tween the cases. Interestingly, the pontine calcification (ob-
served in Case 1, 4, 5) was not detected in our two SLC20A2
cases, in line with the literature (Nicolas et al. 2013a, b);
Chelban et al. (2020) reported that pontin calcification on head
CT may refer toMYORGmutation. These two cases point out
that involvement of the same gene, partly depending on the
different site of mutation, may also have different phenotypes.
The clinical picture of Case 4 was dominated by cerebellar
involvement partially consistent with the head CT picture. The
laboratory results showed alterations consistent with second-
ary hyperparathyroidism. This case is a good presentation of
the clinical situation where, although there is an alteration in
endocrine laboratory parameters, hereditary etiology still pre-
vails (STX16). Although the STX16 deletion detected in our
case affected exons 5–7, the clinical and laboratory picture
(high PTH level, low calcium level, low or normal TSH level,
absence of Albright osteodystrophy) was consistent with the
findings observed in different mutations described previously
(3 kb incl. ex. 4–6; 24.591 kb incl. ex. 2–8 (g.57235162–
57259753del); 4.4 kb incl. ex. 2–4). Interestingly, a case with
a more complex phenotype was described in the ClinVar da-
tabase, in which the same genetic difference was identified as
in our case (NM_001001433.3(STX16):c.393 + 557_792 +
364del - sleep apnea; short nasal bridge; overgrowth; obesity;
exotropia; eczema; Arnold-Chiari malformation; 2–3 toe syn-
dactyly) (Bastepe et al. 2003; Elli et al. 2014; Laspa et al.
2004; Linglart et al. 2005; Mantovani et al. 2007). The expla-
nation for this could be that there is a second unidentified
2137Metab Brain Dis (2021) 36:2131–2139
pathogenic alteration which could be resposible for these non
STX16 related phenotypes, while the development of the ce-
rebral calcification in later years could not be ruled out.
The fifth case illustrates the difficult clinical situation
where, although endocrine abnormalities can be identified,
they cannot be clearly associated with any known hereditary
or non-hereditary disease (Ramos et al., 2017). The young age
of the patient and extensive cerebral calcification would be
primarily in favor of hereditary etiology, however, the change
in parathyroid hormone levels observed may be related to the
pregnancy and the anamnestic syphilis and the elevated anti-
dsDNA antibody level raise the possibility of a secondary
etiology. Deeper laboratory (e.g. autoimmune, serology) and
genetic analysis (whole genome sequencing) could be a for-
ward step in resolving the case with higher certainty, but the
necessity of the even more detailed laboratory evaluation is
questionable and forms a limitation of our study. In contrast,
the sixth case presents a very common and easily diagnosable
etiology. Unfortunately, in clinical practice, follow-up and
adequate treatment (calcium and hydroxy-vitamin D supple-
mentation) of patients with permanent hypocalcemia after thy-
roidectomy is often missing (Miccoli et al. 2012; Petrarca
et al. 2017).
The aim of the present study was to describe and clinically
characterize and compare five different etiologies associated
with cerebral calcification. We conclude that accurate clinical,
radiological and laboratory analyses lead to diagnosis in most
cases. Furthermore, in well-selected cases, aCGH method can
provide more complex information about the potentially rele-
vant genetic alterations.
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